FIELD: chemistry.
SUBSTANCE: invention relates to genetic engineering. Described are clostridial toxins or a hybrid of a clostridial toxin, containing an inactivation splitting site.
EFFECT: invention enables to obtain clostridial toxins which reduce or prevent undesirable side effects associated with dispersion of toxins in target areas.
3 cl, 5 dwg, 9 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR INTRACELLULAR CONVERSION OF SINGLE-STRANDED PROTEINS INTO THEIR DOUBLE-STRANDED FORM | 2011 |
|
RU2569185C2 |
| METHOD OF TREATING URINOGENITAL NEUROLOGICAL DISORDERS WITH USING MODIFIED CLOSTRIDIAL TOXINS | 2008 |
|
RU2491086C2 |
| PHARMACEUTICAL COMPOSITIONS OF CLOSTRIDIA TOXIN | 2009 |
|
RU2535003C2 |
| CATIONIC NEUROTOXINS | 2015 |
|
RU2733493C2 |
| CELLULAR VAMP CLEAVAGE ASSAY | 2017 |
|
RU2807994C2 |
| FUSION PROTEINS AND METHODS OF TREATMENT, PREVENTION OR ALLEVIATION OF PAIN | 2013 |
|
RU2652954C2 |
| THERAPEUTIC FUSION PROTEINS | 2012 |
|
RU2651492C2 |
| RECOMBINANT PROTEIN EXPRESSION IN DOUBLE-STRAND C FORM | 2006 |
|
RU2412253C2 |
| GENETICALLY ENGINEERED CELLS SENSITIVE TO CLOSTRIDIAL NEUROTOXINS | 2020 |
|
RU2824389C2 |
| BIOPREPARATIONS COMPOSITIONS FOR INTRAVESICAL INSTILLATION | 2015 |
|
RU2720991C2 |
